Loading clinical trials...
Loading clinical trials...
The prognosis of patients with relapsed and/or refractory T-cell hematologic malignancies is poor due to lacking sufficient treatment.Anti-CD(cluster of differentiation antigen)19 CAR(chimeric antigen...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Xinqiao Hospital of Chongqing
Collaborators
NCT06390319 · T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoma, and more
NCT03922724 · Peripheral T-cell Lymphomas, Lymphoproliferative Disorders, and more
NCT05475925 · LGLL - Large Granular Lymphocytic Leukemia, Primary Cutaneous Gamma-Delta T-Cell Lymphoma, and more
NCT07523555 · Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL, and more
NCT07388563 · Lymphoma, T Cell, Peripheral, T-cell Lymphoma, and more
Department of Hematology, Xinqiao Hospital
Chongqing, Chongqing Municipality
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions